{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T18:02:58Z","timestamp":1784656978370,"version":"3.55.0"},"reference-count":36,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T00:00:00Z","timestamp":1626220800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:p>Guidelines for the treatment of schizophrenia limit the use of antipsychotic agents to clinically-established maximum doses. This acknowledges both the absence of additional efficacy of dopamine D2 receptor antagonists above a receptor occupancy threshold, and the increases in side effects that can occur at higher doses. These limits restrict the dosing of combinations of antipsychotics as they do single agents; drugs sharing the major antipsychotic mechanism of D2 receptor antagonism will act additively in blocking these receptors.<\/jats:p>\n                  <jats:p>Several newer antipsychotic drugs, including aripiprazole and cariprazine, act as partial agonists at the D2 receptor site and avoid action at several other receptors, effects at which are responsible for some non-dopaminergic adverse effects. This pharmacology imparts different characteristics to the drugs resulting often in a more favourable side effect profile. Their partial agonism, along with high affinities for the D2 receptor, also means that these drugs given adjunctively may in part replace, rather than enhance, the D2 antagonism of other antipsychotic agents. This can result in an improvement in certain side effects without loss of antipsychotic efficacy.<\/jats:p>\n                  <jats:p>This article makes the case for distinguishing the D2 partial agonists from antagonists in defining maximum doses of combined treatments, which would increase the options available to the prescriber, emphasising that pharmacological mechanisms need to be understood in identifying optimal treatments for psychotic illness.<\/jats:p>","DOI":"10.1177\/02698811211026456","type":"journal-article","created":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T03:12:46Z","timestamp":1626232366000},"page":"1030-1036","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":10,"title":["High dose antipsychotic polypharmacy and dopamine partial agonists - time to rethink guidelines?"],"prefix":"10.1177","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9026-7726","authenticated-orcid":false,"given":"Gavin P","family":"Reynolds","sequence":"first","affiliation":[{"name":"Biomolecular Sciences Research Centre, Sheffield Hallam University, Sheffield, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,7,14]]},"reference":[{"key":"bibr1-02698811211026456","doi-asserted-by":"publisher","DOI":"10.1177\/0269881119889296"},{"key":"bibr2-02698811211026456","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116645254"},{"key":"bibr3-02698811211026456","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2006.01.051"},{"key":"bibr4-02698811211026456","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1992.01820070032005"},{"key":"bibr5-02698811211026456","doi-asserted-by":"publisher","DOI":"10.1177\/2045125316672136"},{"key":"bibr6-02698811211026456","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31135-3"},{"key":"bibr7-02698811211026456","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.157.4.514"},{"key":"bibr8-02698811211026456","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbu030"},{"key":"bibr9-02698811211026456","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116642903"},{"key":"bibr10-02698811211026456","unstructured":"Royal College of Psychiatrists (2014) Consensus statement on high-dose antipsychotic medication. Royal College of Psychiatrists. College Report CR190, 2014."},{"key":"bibr11-02698811211026456","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-018-5133-z"},{"key":"bibr12-02698811211026456","doi-asserted-by":"publisher","DOI":"10.1136\/gpsych-2019-100091"},{"key":"bibr13-02698811211026456","doi-asserted-by":"publisher","DOI":"10.1177\/0269881119889296"},{"key":"bibr14-02698811211026456","unstructured":"Barnes TRE, Dye S, Ferrier N, et al. (2014) Consensus statement on high-dose antipsychotic medication. Royal College of Psychiatrists. College Report CR190."},{"key":"bibr15-02698811211026456","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/970730"},{"key":"bibr16-02698811211026456","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116645254"},{"key":"bibr17-02698811211026456","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-021-00801-4"},{"key":"bibr18-02698811211026456","doi-asserted-by":"publisher","DOI":"10.1177\/0004867416641195"},{"key":"bibr19-02698811211026456","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000444"},{"key":"bibr20-02698811211026456","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60733-3"},{"key":"bibr21-02698811211026456","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2019.19010034"},{"key":"bibr22-02698811211026456","unstructured":"National Institute for Health and Care Excellence (2014) Psychosis and schizophrenia in adults: Prevention and management. Clinical Guideline 178. 2014. Available at: https:\/\/www.nice.org.uk\/guidance\/cg178"},{"key":"bibr23-02698811211026456","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-015-4024-9"},{"key":"bibr24-02698811211026456","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.109.070961"},{"key":"bibr25-02698811211026456","doi-asserted-by":"publisher","DOI":"10.1038\/s41537-019-0090-z"},{"key":"bibr26-02698811211026456","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2018.06.070"},{"key":"bibr27-02698811211026456","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2015.01.004"},{"key":"bibr28-02698811211026456","unstructured":"Summary of Product Characteristics. Aripiprazole. Electronic Medicines Compendium. Available at: https:\/\/www.medicines.org.uk\/emc\/product\/7969\/smpc#UNDESIRABLE_EFFECTS"},{"key":"bibr29-02698811211026456","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2018.4320"},{"key":"bibr30-02698811211026456","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000086"},{"key":"bibr31-02698811211026456","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181ee832d"},{"key":"bibr32-02698811211026456","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2017.01.064"},{"key":"bibr33-02698811211026456","unstructured":"James Lind Alliance (2011) Schizophrenia priority setting partnership. Available at: www.jla.nihr.ac.uk\/priority-setting-partnerships\/schizophrenia\/top-10-priorities\/ (accessed 26 April 2021)."},{"key":"bibr34-02698811211026456","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-015-4024-9"},{"key":"bibr35-02698811211026456","first-page":"354","volume":"46","author":"Polcwiartek C","year":"2020","journal-title":"Schizophr Bull"},{"key":"bibr36-02698811211026456","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2018.4320"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811211026456","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02698811211026456","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811211026456","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:10:35Z","timestamp":1777507835000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02698811211026456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,14]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["10.1177\/02698811211026456"],"URL":"https:\/\/doi.org\/10.1177\/02698811211026456","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,14]]}}}